NCT04422639
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have 1-2 lesion(s) greater than 2cm, but less than 5cm in diameter; Lesions must also be appropriate for surgical resection & not previously treated with stereotactic radiosurgery
Exclusions: Patients with leptomeningeal disease; Patients previously treated with whole brain radiotherapy; Patients who have local recurrence of previously treated brain metastasis
https://ClinicalTrials.gov/show/NCT04422639